Many people say they are stressed out, but what does that really look like? How does it impact a company, especially if the company doesn't know? Medibio is attempting to answer that question.
Founded in 1987, the Austrialian digital health company has developed an objective test to assist in the diagnosis of depression, chronic stress, and other mental health disorders. They monitor and analyze circadian heart rate variability to assist in medical diagnosis and is currently running clinical trials. They also run ilumen, a mental health and well-being program, which uses objective measures for the early detection of mental health conditions.
The company recently released the results of a pilot study of ilumen with Compass Group, a British contract food-service company. They reported that the program identified lost productivity hours and led to contacting employees who were identified as being at-risk for mental health disorders.
Medibio has three issued patents in the AI biotech space which relate to methods and systems for monitoring stress conditions. The latest patent teaches receiving a heartbeat record of a patient over time including a sleep period and a pre-sleep period. The data is applied to a computational model to indicate stress conditions.